药物伦理与妊娠:克服治疗性孤儿污名
妊娠期用药的临床决策与咨询缺乏证据支持,孕妇被纳入评估疗效和安全性的药物临床试验仍然很少。本文综述孕妇在临床试验中的现状,强调伦理污名及未来可能的指导方向,并借鉴儿科药理学研究的经验。
要点
- 孕妇被排除在药物临床试验之外导致妊娠期用药证据缺乏。
- FDA已发布多项指南帮助药企设计纳入孕妇的试验方案。
- 儿科药理学研究的进展可为特殊人群试验设计提供借鉴。
核心结论
- 孕妇在药物临床试验中的纳入仍然稀缺,形成治疗性孤儿污名,需克服伦理障碍并借鉴儿科药理学研究经验。
研究设计与样本
- 本文为综述,呈现孕妇在临床试验中的现状,强调伦理污名及未来可能的指导方向。
主要发现
- 支持妊娠期用药临床决策和咨询的证据匮乏。
- 尽管立法机构和倡导组织多方努力,评估疗效和安全性的药物临床试验中孕妇纳入仍然很少。
- 妊娠可能合并多种需要药物干预的合并症,主要针对孕妇但有时对胎儿有继发影响。
关键数值与推荐
- 美国FDA已发布多项关于将孕妇纳入临床试验的指南文件,帮助药企设计方案以确保安全性和符合伦理标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is paucity of evidence to support clinical decision making and counselling related to medication use in pregnancy. Despite multiple efforts from legislative bodies and advocacy groups, the inclusion of pregnant women in clinical drug trials assessing efficacy and safety remains scarce. Pregnancy can be complicated by multiple comorbidities that require pharmacological intervention; these interventions primarily target the pregnant woman but also sometimes have secondary effects for the foetus. The US Food and Drug Administration has issued multiple guidance documents on incorporating pregnant women in clinical trials to aid pharmaceutical companies in designing a protocol to ensure safety and adherence to ethical standards. Advances in paediatric pharmacology studies provide lessons for researchers on the best practice of designing clinical trials with inclusion of patients from special populations. In this review, we present the status of pregnant women in clinical trials, highlighting the ethical stigma and possible future directives.
引用
- Kazma JM, Van Den Anker J, Ahmadzia HK, et al. Pharmacoethics and pregnancy: Overcoming the therapeutic orphan stigma. Br J Clin Pharmacol. 2022. PMID: 34904271. doi:10.1111/bcp.15173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。